Landscapes / Companies
SANGMYUNG innovation not checked
FollowEvery new trial, moved date and filing, and a Monday email
Furthest along
2 in Phase 3
Drugs
2
in active trials
Trials
2 active
2 since 2021
Drugs2
| Drug | How it works | Partner | Stage
Sources: FDA: the drug development process, ClinicalTrials.gov glossary | Next date
| Details |
|---|---|---|---|---|---|
— |
Phase 3 | Jul 2027Phase 3 trial completes | |||
| Next date | Jul 2027 · Phase 3 trial completes | ||||
| Also tested for | Retinal Vein Occlusion With Macular Edema | ||||
| Open drug page | |||||
— |
Phase 3 | Dec 2027Phase 3 trial completes | |||
| Next date | Dec 2027 · Phase 3 trial completes | ||||
| Also tested for | Neovascular (Wet) Age-related Macular Degeneration Without Polypoidal Choroidal Vasculopathy | ||||
| Open drug page | |||||
About
- SEC filings
- None: it does not file with the US SEC
- Sources
- ClinicalTrials.gov updated 19 Nov 2026 Industry-sponsored drug trials since 2021